Caidya Secures $165 Million in Funding to Elevate Clinical Research Services Worldwide

Caidya, a pioneering multi-therapeutic clinical research organization (CRO), has proudly announced the successful completion of a $165 million funding round aimed at bolstering its mission of delivering exceptional clinical services to innovators across the globe. Established in 2021 through the strategic merger of dMed and Clinipace, Caidya has rapidly grown to encompass nearly 1,800 employees and establish operations in over 30 countries. This latest influx of capital will enable Caidya to enhance its proprietary clinical technology, known for fostering trial transparency and data-driven decision-making—cornerstones of their elevated customer experience. With a robust range of services that supports partners from pre-IND strategy through clinical development to submission and post-marketing surveillance, this funding will play a pivotal role in expanding Caidya’s therapeutic expertise and operational capacities. The financial boost will not only facilitate investment in advanced technologies but also support the recruitment of top-tier talent and expansion into emerging markets, ensuring that Caidya remains at the forefront of clinical excellence in a fast-evolving industry. As the need for reliable and efficient clinical research solutions continues to grow, Caidya is well-positioned to drive innovation, support drug development, and help bring vital therapies to patients in need. With this significant funding, Caidya reaffirms its commitment to transforming the clinical research landscape and enhancing the success of its partners worldwide.